AI in Pharma: From Experimentation to Execution

Executive Summary

The life sciences industry is at a critical inflection point. Artificial intelligence (AI) has rapidly evolved from experimentation into expectation, driving tangible productivity, efficiency, and user-experience gains across the pharmaceutical value chain. Yet, many organizations remain trapped in “pilot purgatory,” where proof-of-concepts fail to scale or demonstrate measurable ROI.

This white paper outlines how leading pharmaceutical companies are shifting from fragmented experimentation to purpose-built AI initiatives that deliver business value. Drawing insights from industry leaders and recent discussions at Dreamforce, we explore how organizations can realign business processes, measure success with clarity, and accelerate transformation through co-sponsorship, accessibility, and talent.